Bringing radical innovation to the $10 billion X-ray industry.
Tylor Garland, Founder and CEO of Boombang, an Innovation Agency / Venture Incubator based in Los Angeles, California, has spent his career developing a proven, deeply integrated methodology to launching products, brands and business strategies, which translates as well in boardrooms as it does in creative war rooms. His work has been featured in Wired, GQ, and Fortune Magazine, and has been on display at the MoMA and the Whitney, receiving numerous awards including recognition from IDSA and Red Dot.
Tylor’s strategy has paid off with over 500 products launched since Boombang’s inception in 2002, generating close to $3 billion in retail revenue. During this short time period, Boombang has amassed an impressive portfolio of brands, products and intellectual property, in addition to securing global design partnerships with top-notch companies including Harman International, Simmons, Disney, Viacom, ConAgra, Logitech, Church & Dwight, Target and Newell Rubbermaid.
Tylor brought battle-hardened experience from over a decade of working with renowned international design agencies to his launch of Boombang. He previously held posts as Director at Fitch Inc. and Managing Director of Product Development and Engineering at frog design, where he worked with such best-in-class companies as Apple, IBM, Packard Bell, AT&T, Iomega, Harman International, Mattel, Microsoft, Nokia, Samsung and Ford Motor Company. He stepped out in the wild blue yonder with Boombang because he sensed a growing gap between the world of product innovation and successful product commercialization. He enjoys sharing his philosophy of bringing together the creative space and the marketplace as Art Center faculty and guest lecturer for organizations such as CCA, UCLA, Drucker and Harvard Business School.
Transforming Simmons from the better mattress company into the better sleep company.
Simmons was looking to introduce the next big thing in mattresses. Boombang research revealed that 85% of adults say they don’t sleep well, but rarely blame their mattress, while sleep-related spending has reached over $30 billion.
Boombang designed an expanded suite of bedroom solutions for Simmons, reaching far beyond the familiar narrative of comfort and support to encompass the total sleep environment.
Boombang suggested shifting Simmons’ focus from the Bed of Tomorrow to the Bedroom of Tomorrow. This would not only differentiate Simmons from its competitors, but also create new opportunities to connect with consumers outside of traditional channels—all without any significant increase in advertising costs. Welcome to the Sleep Revolution.
With over 800K units sold in two years, the category-leading Perfect Fitness Ab Carver — one of this century’s most successful home fitness products — was researched, designed and engineered by Boombang in collaboration with the Perfect Fitness team.
Boombang started with a sketch on a napkin and a wish list of desired features that Perfect Fitness thought would increase the ab wheel’s versatility and justify a premium market position.
Numerous prototypes followed, resulting in our invention of a spring and clutch system with adjustable levels of resistance, and a motorcycle-inspired contact patch allowing users to not only roll but also carve their abs.
Throughout the development, product testing, branding, and factory handoff, Boombang and Perfect Fitness functioned as a unified team.
Boombang recognized an opportunity to make the MRI experience more pleasant for patients and more effective for researchers.
SMRT Image offers two-way communication between patients and medical professionals, enhanced fMRI brain mapping capabilities, and sophisticated audio-visual entertainment for patients during MRIs.
By reducing the need for repeat scans due to patient movement by up to 15%, as well as the need for pricey medications and anesthesia during MRIs, SMRT Image pays for itself in less than a year. For pharmaceutical companies, SMRT Image has been proven to reduce the speed of transition from development to real-world delivery of new drugs by up to 50% and cost by up to 33%.
Comments are closed.